Drugs for cardiovascular disease in India: perspectives of pharmaceutical executives and government officials on access and development-a qualitative analysis
Open Access
- 2 May 2016
- journal article
- research article
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 9 (1) , 1-11
Abstract
India shoulders the greatest global burden of cardiovascular diseases (CVDs), which are the leading cause of mortality worldwide. Drugs are the bedrock of treatment and prevention of CVD. India’s pharmaceutical industry is the third largest, by volume, globally, but access to CVD drugs in India is poor. There is a lack of qualitative data from government and pharmaceutical sectors regarding CVD drug development and access in India. By purposive sampling, we recruited either Indian government officials, or pharmaceutical company executives. We conducted a stakeholder analysis via semi-structured, face-to-face interviews in India. Topic guides allow for the exploration of key issues across multiple interviews, along with affording the interviewer the flexibility to examine matters arising from the discussions themselves. After transcription, interviews underwent inductive thematic analysis. Ten participants were interviewed (Government Officials: n = 5, and Pharmaceutical Executives: n = 5). Two themes emerged: i) ‘Policy-derived Factors’; ii) ‘Patient- derived Factors’ with three findings. First, both government and pharmaceutical participants felt that the focus of Indian pharma is shifting to more complex, high-quality generics and to new drug development, but production of generic drugs rather than new molecular entities will remain a major activity. Second, current trial regulations in India may restrict India’s potential role in the future development of CVD drugs. Third, it is likely that the Indian government will tighten its intellectual property regime in future, with potentially far-reaching implications on CVD drug development and access. Our stakeholder analysis provides some support for present patent regulations, whilst suggesting areas for further research in order to inform future policy decisions regarding CVD drug development and availability. Whilst interviewees suggested government policy plays an important role in shaping the industry, a significant force for change was ascribed to patient-derived factors. This suggests a potential role for Indian initiatives that market the unique advantages of its patient population for drug research in influencing national and multinational pharmaceutical companies to undertake CVD drug development in India, rather than simply IP policy-directed factors.Keywords
Funding Information
- European Research Council (339239)
This publication has 39 references indexed in Scilit:
- A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case studyBMC Pharmacology and Toxicology, 2013
- Pathways to catastrophic health expenditure for acute coronary syndrome in Kerala: ‘Good health at low cost’?BMC Public Health, 2012
- The Economic impact of Non-communicable Diseases on households in IndiaGlobalization and Health, 2012
- Influencing policy change: the experience of health think tanks in low- and middle-income countriesHealth Policy and Planning, 2011
- A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in IndiaIndian Journal of Pharmacology, 2011
- Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry dataThe Lancet, 2008
- HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare?PLOS ONE, 2007
- How Many Interviews Are Enough?Field Methods, 2006
- Using thematic analysis in psychologyQualitative Research in Psychology, 2006
- Adherence to MedicationNew England Journal of Medicine, 2005